Last reviewed · How we verify
Other approved anti-cancer therapy
Other approved anti-cancer therapy is a Small molecule drug developed by Riboscience, LLC.. It is currently in Phase 1 development.
At a glance
| Generic name | Other approved anti-cancer therapy |
|---|---|
| Sponsor | Riboscience, LLC. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1, PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination (PHASE1, PHASE2)
- Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma (PHASE2)
- Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
- Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors (PHASE1)
- Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (PHASE1, PHASE2)
- Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other approved anti-cancer therapy CI brief — competitive landscape report
- Other approved anti-cancer therapy updates RSS · CI watch RSS
- Riboscience, LLC. portfolio CI
Frequently asked questions about Other approved anti-cancer therapy
What is Other approved anti-cancer therapy?
Other approved anti-cancer therapy is a Small molecule drug developed by Riboscience, LLC..
Who makes Other approved anti-cancer therapy?
Other approved anti-cancer therapy is developed by Riboscience, LLC. (see full Riboscience, LLC. pipeline at /company/riboscience-llc).
What development phase is Other approved anti-cancer therapy in?
Other approved anti-cancer therapy is in Phase 1.